Chronotherapy in dipper and nondipper hypertension patients, researching sodium in 24 hours urine and serum urotensin II levels

Fatma Akdag Kahvecioglu; Muhittin Ertilav; Perihan Varim; Ceyhun Varim

doi:10.18203/2320-6012.ijrms20241867

Authors

Fatma Akdag Kahvecioglu Department of Internal Medicine, Abant Izzet Baysal University Medicine Faculty, Bolu, Turkey
Muhittin Ertilav Department of Nephrology, Abant Izzet Baysal University Medicine Faculty, Bolu, Turkey
Perihan Varim Department of Cardiology, Sakarya University Medicine Faculty, Sakarya, Turkey
Ceyhun Varim Department of Internal Medicine, Sakarya University Medicine Faculty, Sakarya, Turkey

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241867

Keywords:

Dipper, Hypertension, Nondipper, Serum urotensin II

Abstract

Background: The aim of this research was to study the chronotherapy in patients with differentiated dipper and nondipper hypertension, researching the differences between sodium in 24 hours urine and serum urotensin II.

Methods: About 32 nondipper and 29 dipper hypertension patients who have study admission criteria, sodium levels in 24 hours urine, serum urotensin II levels and routine biochemical laboratory tests of were studied. The statistical relationship between the results was analyzed.

Results: In the patient group we examined, nondipper patients were found older and predominantly seen in the female patient population. We determined that the dipper patients differed significantly in family history from nondipper patients. Although it is not statistical significance, we observed accordance of treatment who nondipper patients was worse, we have found that serum urotensin II levels can be used at this distinction.

Conclusions: It is important to distinguish nondipper and dipper hypertension in terms of the prognosis of hypertension and the efficacy of the treatment. For this reason, we want to underline that nondipper patients are older and predominantly seen in the female patient population. Although left ventricular mass index is important in the course and outcome of hypertension, we determined that is was not useful in distinguishing dipper-nondipper hypertension. We think that serum urotensin II levels will be useful in determining the efficacy of the treatment used, the prognosis of hypertension and the differentiation of nondipper-dipper hypertension.

Metrics

Metrics Loading ...

References

Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypert. 1995;25(3):305-13.

World Health Organization. International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-92.

Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117-24.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypert. 2003;42(6):1206-52.

Alderman MH, Madhavan S, Cohen H, Sealey JE, Laragh JH. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hyperten. 1995;25(6):1144-52.

Alderman MH, Cohen H, Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). The Lancet. 1998;351(9105):781-5.

Nakandakare ER, Charf AM, Santos FC, Nunes VS, Ortega K, Lottenberg AM, et al. Dietary salt restriction increases plasma lipoprotein and inflammatory marker concentrations in hypertensive patients. Atheroscl. 2008;200(2):410-6.

Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atheroscl. 2004;176(1):117-23.

Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, et al. Direct actions of urotensin II on the heart implications for cardiac fibrosis and hypertrophy. Circulat Res. 2003;93(3):246-53.

Buyon JP, Winchester RJ, Slade SG, Arnett F, Copel J, Friedman D, et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children.comparison of enzyme‐linked immunosorbent assay and immunoblot for measurement of anti–ss‐a/ro and anti–ss‐b/la antibodies. Arthr Rheumat. 1993;36(9):1263-73.

Fessler BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Cli North America. 1995;21(1):81-98.

O'Brien E, Sheridan J, O'Malley K. Dippers and nondippers. The Lancet. 1988;332(8607):397.

Fariello R, Boni E, Crippa M, Damiani G, Corda L, Valenti L, et al. Ambulatory-determined 24- hour blood pressure in mild hypertensives and in normotensives. Angiol. 1996;47(10):957-62.

Grandi AM, Broggi R, Jessula A, Laurita E, Cassinerio E, Piperno F, et al. Relation of extent of nocturnal blood pressure decrease to cardiovascular remodeling in never-treated patients with essential hypertension. Am J Cardiol. 2002;89(10):1193-6.

O'brien E, Staessen J. Normotension and hypertension as defined by 24-hour ambulatory blood pressure monitoring. Blood Press. 1995;4(5):266-82.

Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulat. 1990;81(2):528-36.

Rizzo V, Di Maio F, Campbell SV, Tallarico D, Petretto F, Lorido A, et al. Left ventricular function, cardiac dysrhythmias, atrial activation, and volumes in nondipper hypertensive individuals with left ventricular hypertrophy. Am Heart J. 2000;139(3):529-36.

Hermida RC, Ayala DE, Fernandez JR, Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypert. 2007;50(4):715-22.

Hermida RC, Calvo C, Ayala DE, Fernandez JR, Covelo M, Mojon A, et al. Treatment of nondipper hypertension with bedtime administration of valsartan. J Hypertens. 2005;23(10):1913-22.

Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Chronobiol Internat. 2010;27(6):1287-303.

Arıcı M, Altun B, Erdem Y. Turkish Society of Hypertension and Kidney Diseases Turkish Hypertension Prevalence Study. J Hypert. 2005;23(10):1817-23.

Zhou B, Stamler J, Dennis B, Moag-Stahlberg A, Okuda N, Robertson C, et al. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study. J Hum Hypert. 2003;17(9):623-30.

Group ICR. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ. 1988;297:319-28.

Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous function in nondipper essential hypertensive subjects evaluation by power spectral analysis of heart rate variability. Hypert. 1995;26(5):808-14.

Kuwajima I, Suzuki Y, Shimosawa T, Kanemaru A, Hoshino S, Kuramoto K. Diminished nocturnal decline in blood pressure in elderly hypertensive patients with left ventricular hypertrophy. Am Heart J. 1992;123(5):1307-11.

Erbay AR, Meriç M, Alacam H, Zengin H, Akin F, Okur A, et al. Serum urotensin II levels in patients with nondipper hypertension. Clinical and experimental hypertension (New York, NY: 1993). 2013;35(7):506-11.

Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401(6750):282-6.

Tölle M, van der Giet M. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides. 2008;29(5):743-63.

Maguire JJ, Davenport AP. Is urotensin‐II the new endothelin? Brit J Pharmacol. 2002;137(5):579-88.